SciELO - Scientific Electronic Library Online

 
vol.32 issue3Cost avoided in drugs derived from the participation of patients in oncology clinical trialsEvaluation of the safety profile of the drug lopinavir/ritonavir (Lpv/r) in suspected or confirmed COVID-19 patients author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la OFIL

On-line version ISSN 1699-714XPrint version ISSN 1131-9429

Abstract

BAEZ-GUTIERREZ, N; RODRIGUEZ-RAMALLO, H  and  ALVAREZ-DEL VAYO-BENITO, C. Incidence and management of etoposide hypersensitivity in pediatrics. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.3, pp.235-237.  Epub Sep 25, 2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2022000300004.

Introduction:

Etoposide is widely used in pediatric chemotherapy. At the moment, there is conflicting data in the literature on the incidence of etoposide hypersensitivity. The aim of this study is to assess etoposide hypersensitivity incidence and to evaluate potential risk factors for hypersensitivity in pediatrics.

Methods:

Retrospective study of pediatric patients treated with etoposide since June 2013 until September 2020. Symptoms of hypersensitivity, grade of hypersensitivity reaction according to the Common Terminology Criteria for Adverse Events guidelines and management of hypersensitivity reaction data were collected.

Results:

213 patients were treated with etoposide during the period of the study. The mean age was 6.8 (range 0.2-17 years), 58.7% were male. Doses administered ranged from 100-200 mg/m2 and from 2.5-6 mg/kg, median infusion rate was 55 (2-200) mg/h and median infusion concentration was 0.3 (0.2-0.5) mg/ml. Hypersensitivity reactions occurred in 23 (10.8%) patients, 3 and 20 cases were classified as grade I and II respectively. All hypersensitivity reactions were successfully managed with medication and reduction of the infusion rate. No statistical significant association between the variables collected and the apparition of hypersensitivity reactions was found.

Conclusions:

The incidence of hypersensitivity reaction was higher than the described in the summary of products characteristics. All reactions were mild being resolved by standard treatment.

Keywords : Etoposide; hypersensitivity; incidence; pediatrics.

        · abstract in Spanish     · text in English     · English ( pdf )